Insider Selling: NuVasive EVP Sells 10,095 Shares of Stock (NUVA)
NuVasive (NASDAQ:NUVA) EVP Jason Hannon sold 10,095 shares of NuVasive stock on the open market in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $36.60, for a total transaction of $369,477.00. Following the transaction, the executive vice president now directly owns 8,899 shares of the company’s stock, valued at approximately $325,703. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Canaccord Genuity raised their price target on shares of NuVasive from $34.00 to $51.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann upgraded shares of NuVasive from a “market perform” rating to an “outperform” rating in a research note to investors on Wednesday. They now have a $45.00 price target on the stock, up previously from $33.00. Finally, analysts at Goldman Sachs Group Inc. upgraded shares of NuVasive from a “sell” rating to a “neutral” rating in a research note to investors on Thursday, January 16th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $31.84.
Shares of NuVasive (NASDAQ:NUVA) traded up 0.05% on Thursday, hitting $38.27. The stock had a trading volume of 411,875 shares. NuVasive has a one year low of $16.77 and a one year high of $38.79. The stock has a 50-day moving average of $33.65 and a 200-day moving average of $28.23. The company’s market cap is $1.708 billion.
NuVasive (NASDAQ:NUVA) last announced its earnings results on Tuesday, October 29th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, analysts predict that NuVasive will post $1.16 earnings per share for the current fiscal year.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.